Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versus the standard of care in HIV-1 infected patients with sustained virological response during HAART [Studio clinico randomizzato di non inferiorita sulla efficacia e sicurezza dell uso di efavirenz/tenofovir/emtricitabina in combinazione fissa (Atripla) somministrato a giorni alterni comparato con lo standard of care in pazienti con infezione da HIV-1 in soppressione virologica sotto HAART].
Latest Information Update: 17 Feb 2019
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Pharmacogenomic; Therapeutic Use
- 05 Feb 2019 Status changed from recruiting to completed.
- 05 Feb 2019 Results published in the AIDS
- 06 Sep 2012 New trial record